Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: povidone; microcrystalline cellulose; maize starch; pregelatinised maize starch; sodium hydroxide; magnesium stearate; colloidal anhydrous silica; meglumine; sorbitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; meglumine; magnesium stearate; maize starch; colloidal anhydrous silica; sodium hydroxide; povidone; sorbitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, multilayer - excipient ingredients: colloidal anhydrous silica; sodium hydroxide; sorbitol; magnesium stearate; pregelatinised maize starch; povidone; microcrystalline cellulose; maize starch; meglumine; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sorbitol; sodium hydroxide; microcrystalline cellulose; povidone; colloidal anhydrous silica; maize starch; pregelatinised maize starch; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - candesartan cilexetil, quantity: 8 mg - tablet, uncoated - excipient ingredients: magnesium stearate; carmellose calcium; glyceryl monostearate; hyprolose; iron oxide red; lactose monohydrate; maize starch - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function, left ventricular ejection fraction less than or equal to 40 percent, as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - candesartan cilexetil, quantity: 4 mg - tablet, uncoated - excipient ingredients: hyprolose; glyceryl monostearate; magnesium stearate; carmellose calcium; lactose monohydrate; maize starch - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function, left ventricular ejection fraction less than or equal to 40 percent, as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: hyprolose; iron oxide red; glyceryl monostearate; magnesium stearate; maize starch; carmellose calcium; lactose monohydrate - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function, left ventricular ejection fraction less than or equal to 40 percent, as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; glyceryl monostearate; maize starch; hyprolose; iron oxide red; carmellose calcium - treatment of hypertension. treatment of patients with heart failure and impaired left ventricular systolic function, left ventricular ejection fraction less than or equal to 40 percent, as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; povidone; colloidal anhydrous silica; croscarmellose sodium; crospovidone; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.